AMGEN Inc.

NASDAQ:AMGN   11:27:09 AM EDT
225.00
+1.00 (+0.45%)
Products, Regulatory

Amgen Announces Positive Top-Line Results From Otezla Phase 3 Discreet Study In Moderate To Severe Genital Psoriasis

Published: 12/01/2021 21:21 GMT
AMGEN Inc. (AMGN) - Amgen Announces Positive Top-line Results From Otezla® (apremilast) Phase 3 Discreet Study in Moderate to Severe Genital Psoriasis.
Amgen Inc - Otezla Resulted in Clinically and Statistically Significant Improvements in Measures of Genital Psoriasis at Week 16 Compared With Placebo.
Amgen Inc - Safety and Tolerability Data Were Consistent With Known Safety Profile of Otezla.
Amgen Inc - in Addition, All Secondary Endpoints Were Also Met.
Amgen Inc - Study is Ongoing and is Planned to Complete in First Half of 2022.